Abstract
The concept of using blood products to control bleeding in people with hemophilia is almost two centuries old. In more recent times, transfusions of whole blood have been replaced by plasma, cryoprecipitate, plasma-derived FVIII concentrates, and currently, recombinant concentrates. Products have been improved by using affinity chromatography purification, viral inactivation steps, elimination of extraneous human proteins, and most recently, modifications to prolong their duration of action. The principal drawbacks of the currently available concentrates are stimulation of inhibitor (antibody) formation, requirement for intravenous infusion, and cost. Current research is focused on the development of less antigenic products and new delivery systems.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
